Prostate specific membrane antigen knockdown impairs the tumorigenicity of LNCaP prostate cancer cells by inhibiting the phosphatidylinositol 3-kinase/Akt signaling pathway

被引:6
|
作者
Guo Zhenghui [1 ]
Lai Yiming [1 ]
Du Tao [2 ]
Zhang Yiming [1 ]
Chen Jieqing [1 ]
Bi Liangkuan [1 ]
Lin Tianxin [1 ]
Liu Hao [1 ]
Wang Wei [3 ]
Xu Kewei [1 ]
Jiang Chun [1 ]
Han Jinli [1 ]
Zhang Caixia [1 ]
Dong Wen [1 ]
Huang Jian [1 ]
Huang Hai [1 ]
机构
[1] Sun Yat Sen Univ, Dept Urol, Sun Yat Sen Mem Hosp, Guangzhou 510120, Guangdong, Peoples R China
[2] Sun Yat Sen Univ, Sun Yat Sen Mem Hosp, Prenatal Diag Ctr, Guangzhou 510120, Guangdong, Peoples R China
[3] Guangzhou Mil Command Peoples Liberat Army, Gen Hosp, Dept Urol, Guangzhou 510000, Guangdong, Peoples R China
基金
中国国家自然科学基金;
关键词
prostate cancer; LNCaP cells; prostate-specific membrane antigen; RNA interference; PI3K/Akt pathway; tumorigenicity; PROTEIN EXPRESSION; PTEN EXPRESSION; IN-VITRO; AKT; GROWTH; GENE; PSMA; ADENOCARCINOMA; INACTIVATION; RECURRENCE;
D O I
10.3760/cma.j.issn.0366-6999.20132707
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background Prostate specific membrane antigen (PSMA) can facilitate the growth, migration, and invasion of the LNCaP prostate cancer cell lines, but the underlying molecular mechanisms have not yet been clearly defined. Here, we investigated whether PSMA serves as a novel regulator of the phosphatidylinositol 3-kinase (PI3K)/Akt signaling by employing PSMA knockdown model and PI3K pharmacological inhibitor (LY294002) in LNCaP prostate cancer cells. Methods PSMA knockdown had been stably established by transfecting with lentivirus-mediated siRNA in our previous study. Then, LNCaP cells were divided into interference, non-interference, and blank groups. We first testified the efficacy of PSMA knockdown in our LNCaP cell line. Then, we compared the expression of PSMA and total/activated Akt by Western blotting in the above three groups with or without LY294002 treatment. Furthermore, immunocytochemistry was performed to confirm the changes of activated Akt (p-Akt, Ser473) in groups. Besides, cell proliferation, migration, and cell cycle were measured by CCK-8 assay, Transwell analysis, and Flow cytometry respectively. Results After PSMA knockdown, the level of p-Akt (Ser473) but not of total-Akt (Akt1/2) was significantly decreased when compared with the non-interference and blank groups. However, LY294002 administration significantly reduced the expression of p-Akt (Ser473) in all the three groups. The results of immunocytochemistry further confirmed that PSMA knockdown or LY294002 treatment was associated with p-Akt (Ser473) down-regulation. Decrease of cell proliferation, migration, and survival were also observed upon PSMA knockdown and LY294002 treatment. Conclusions Taken together, our results reveal that PI3K/Akt signaling pathway inhibition may serve as a novel molecular mechanism in LNCaP prostate cancer cells of PSMA knockdown and suggest that Akt (Ser473) may play a critical role as a downstream signaling target effector of PSMA in this cellular model.
引用
收藏
页码:929 / 936
页数:8
相关论文
共 50 条
  • [31] Anti-prostate specific membrane antigen designer T cells for prostate cancer therapy
    Ma, QZ
    Safar, M
    Holmes, E
    Wang, YW
    Boynton, AL
    Junghans, RP
    PROSTATE, 2004, 61 (01) : 12 - 25
  • [32] Phosphatidylinositol-3-Kinase/Akt Signaling Pathway and Kidney Cancer, and the Therapeutic Potential of Phosphatidylinositol-3-Kinase/Akt Inhibitors
    Porta, Camillo
    Figlin, Robert A.
    JOURNAL OF UROLOGY, 2009, 182 (06) : 2569 - 2577
  • [33] Prolonged androgen deprivation leads to downregulation of androgen receptor and prostate-specific membrane antigen in prostate cancer cells
    Liu, Tiancheng
    Wu, Lisa Y.
    Fulton, Melody D.
    Johnson, Jacqueline M.
    Berkman, Clifford E.
    INTERNATIONAL JOURNAL OF ONCOLOGY, 2012, 41 (06) : 2087 - 2092
  • [34] Prostate cancer targeting motifs: Expression of αvβ3, neurotensin receptor 1, prostate specific membrane antigen, and prostate stem cell antigen in human prostate cancer cell lines and xenografts
    Taylor, Robert M.
    Severns, Virginia
    Brown, David C.
    Bisoffi, Marco
    Sillerud, Laurel O.
    PROSTATE, 2012, 72 (05) : 523 - 532
  • [35] Tanshinone IIA Induces Mitochondria Dependent Apoptosis in Prostate Cancer Cells in Association with an Inhibition of Phosphoinositide 3-Kinase/AKT Pathway
    Won, Suk-Hyun
    Lee, Hyo-Jeong
    Jeong, Soo-Jin
    Lee, Hyo-Jung
    Lee, Eun-Ok
    Jung, Deok-Beom
    Shin, Ji-Min
    Kwon, Tae-Rin
    Yun, Sun-Mi
    Lee, Min-Ho
    Choi, Seung-Hoon
    Lue, Junxuan
    Kim, Sung-Hoon
    BIOLOGICAL & PHARMACEUTICAL BULLETIN, 2010, 33 (11) : 1828 - 1834
  • [36] Activation of the phosphatidylinositol 3-kinase/Akt pathway prevents radiation-induced apoptosis in breast cancer cells
    Söderlund, K
    Pérez-Tenorio, G
    Stål, O
    INTERNATIONAL JOURNAL OF ONCOLOGY, 2005, 26 (01) : 25 - 32
  • [37] Antrocin Sensitizes Prostate Cancer Cells to Radiotherapy through Inhibiting PI3K/AKT and MAPK Signaling Pathways
    Chen, Yu-An
    Tzeng, David T. W.
    Huang, Yi-Ping
    Lin, Chun-Jung
    Lo, U-Ging
    Wu, Chia-Lin
    Lin, Ho
    Hsieh, Jer-Tsong
    Tang, Chih-Hsin
    Lai, Chih-Ho
    CANCERS, 2019, 11 (01):
  • [38] Preferential association of prostate cancer cells expressing prostate specific membrane antigen to bone marrow matrix
    Barwe, Sonali P.
    Maul, Raymond S.
    Christiansen, Jason J.
    Anilkumar, Gopalakrishnapillai
    Cooper, Carlton R.
    Kohn, Donald B.
    Rajasekaran, Ayyappan K.
    INTERNATIONAL JOURNAL OF ONCOLOGY, 2007, 30 (04) : 899 - 904
  • [39] Inhibition of focal adhesion kinase induces apoptosis in bladder cancer cells via Src and the phosphatidylinositol 3-kinase/Akt pathway
    Kong, Debo
    Chen, Feng
    Sima, Ni
    EXPERIMENTAL AND THERAPEUTIC MEDICINE, 2015, 10 (05) : 1725 - 1731
  • [40] Cell detachment modulates TRAIL resistance in ovarian cancer cells by downregulating the phosphatidylinositol 3-kinase/Akt pathway
    Lane, D.
    Cartier, A.
    Rancourt, C.
    Piche, A.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2008, 18 (04) : 670 - 676